{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Tirzepatide?<\/h3>\n<p style=\"margin: 0;\"><strong>Tirzepatide<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active studies molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published studies, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, estrutura baseada em GIP com Aib<sup>2<\/sup>, Aib<sup>13<\/sup>, e Lys<sup>20<\/sup>-C20 di\u00e1cido graxo acila\u00e7\u00e3o via espa\u00e7ador \u03b3Glu-\u03b3Glu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de uso mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Tirzepatida?<\/h2>\n<p><strong>Tirzepatide<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide&#8217;s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile. Tirzepatide&#8217;s well-characterised structure has empirical formula C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published studies. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For broader incretin studies, see our <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> p\u00e1ginas de produtos. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Co-Agonismo Dual dos Receptores GLP-1\/GIP<\/h2>\n<p>O que diferencia a tirzepatida dos pept\u00eddeos de incretina \u00fanica anteriores \u00e9 sua <strong>ativa\u00e7\u00e3o equilibrada de dois receptores distintos<\/strong>, each contributing complementary metabolic effects observed in published studies:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor GLP-1 \u2014 saciedade, secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2, esvaziamento g\u00e1strico<\/strong> \u2014 O Tirzepatide se liga ao receptor GLP-1 com afinidade compar\u00e1vel ao GLP-1 nativo, ativando G\u03b1<sub>s<\/sub>-adenilil ciclase acoplada e sinaliza\u00e7\u00e3o cAMP\/PKA downstream. Isso produz os efeitos can\u00f4nicos do GLP-1: potencia\u00e7\u00e3o dependente de glicose da secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2 pancre\u00e1ticas, supress\u00e3o de glucagon das c\u00e9lulas \u03b1, retardo do esvaziamento g\u00e1strico e efeitos centrais de supress\u00e3o do apetite via neur\u00f4nios POMC do n\u00facleo arqueado. Este mecanismo se sobrep\u00f5e ao do semaglutida.<\/li>\n<li><strong>Ativa\u00e7\u00e3o do receptor GIP \u2014 lip\u00f3lise de adip\u00f3citos, gasto energ\u00e9tico, suporte \u00e0s c\u00e9lulas \u03b2<\/strong> \u2014 The GIP component is what makes tirzepatide pharmacologically distinct. GIP receptor activation enhances insulin secretion in a glucose-dependent manner (complementary to GLP-1&#8217;s effect), but also acts on adipocytes to promote lipolysis under fasting conditions while supporting triglyceride storage in the fed state. Studies suggests GIP-receptor signaling also raises resting energy expenditure modestly and acts in CNS regions distinct from GLP-1, including the dorsomedial hypothalamus. The net effect is an additive body-weight signal beyond what GLP-1 alone produces.<\/li>\n<li><strong>Equil\u00edbrio do receptor e ajuste fino estrutural<\/strong> \u2014 In radioligand-binding assays, tirzepatide shows higher affinity for the GIP receptor than for the GLP-1 receptor \u2014 an unusual ratio that distinguishes it from earlier dual-agonist candidates. The asymmetry is intentional: the GIP backbone allows higher GIP-receptor potency while the engineered modifications preserve sufficient GLP-1 activity. Tirzepatide is sometimes described as &#8220;GIP-biased&#8221; in receptor pharmacology, which has implications for the differential signalling observed in study models.<\/li>\n<\/ul>\n<p>The C20 fatty diacid acyl tether at lysine 20 binds reversibly to circulating serum albumin, forming a peptide depot that protects tirzepatide from renal clearance and produces the ~120-hour plasma half-life. The double Aib substitution (positions 2 and 13) prevents DPP-4 cleavage at two distinct sites, providing redundant proteolytic protection. Together these structural features convert what would otherwise be a short-acting incretin into a once-weekly peptide. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Tirzepatide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Controle glic\u00eamico e sensibilidade \u00e0 insulina<\/strong> \u2014 frente a frente com semaglutida e outros monoagonistas de GLP-1 (Frias et al., NEJM 2021 SURPASS-2); modelos de roedores db\/db, ZDF e dieta hiperlip\u00eddica; efeitos sobre substitutos de HbA1c, glicemia de jejum e par\u00e2metros de clamp hiperinsulin\u00eamico-euglic\u00eamico<\/li>\n<li><strong>Body weight and adiposity studies<\/strong> \u2014 the SURMOUNT-1 trial showed ~22% body weight reduction at 15\u00a0mg weekly over 72 weeks, the largest single-peptide effect documented in clinical studies at the time; rodent DIO models, body composition (DEXA \/ MRI), respiratory exchange ratio<\/li>\n<li><strong>MASLD\/MASH (doen\u00e7a hep\u00e1tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> \u2014 conte\u00fado de triglicer\u00eddeos hep\u00e1ticos, ALT\/AST, estadiamento de fibrose; conjunto de dados do estudo SYNERGY-NASH<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efeitos sobre press\u00e3o arterial, perfis lip\u00eddicos, progress\u00e3o da aterosclerose em ApoE<sup>-\/-<\/sup> modelos; dados de desfechos cardiovasculares do SURPASS-CVOT<\/li>\n<li><strong>Sleep apnoea studies<\/strong> \u2014 gravidade da apneia obstrutiva do sono, \u00edndice de apneia-hipopneia no conjunto de dados SURMOUNT-OSA<\/li>\n<li><strong>Prote\u00e7\u00e3o renal em modelos de nefropatia diab\u00e9tica<\/strong> \u2014 albumin\u00faria, taxa de filtra\u00e7\u00e3o glomerular, expans\u00e3o mesangial em doen\u00e7a renal diab\u00e9tica induzida por estreptozotocina e em camundongos Akita<\/li>\n<li><strong>Comparative incretin peptide studies<\/strong> \u2014 refer\u00eancia para compara\u00e7\u00f5es de agonista duplo vs agonista \u00fanico vs agonista triplo. Veja nosso <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\">Guia Retatrutide vs Tirzepatide<\/a> e ao <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> p\u00e1gina do produto para comparadores relacionados.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o tirzepatide se encaixa no cen\u00e1rio de pept\u00eddeos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (agonista triplo de GLP-1\/GIP\/glucagon, o comparador de pr\u00f3xima gera\u00e7\u00e3o) e <a href=\"https:\/\/medsbase.com\/pt-br\/ozempic-vs-mounjaro\/\">nosso guia Ozempic vs Mounjaro<\/a>. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Tirzepatide in eleven lyophilized vial strengths covering the full dose-titration range from pilot dosing through multi-month bulk protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosagem piloto, titula\u00e7\u00e3o de baixo n\u00edvel, ciclos curtos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maintenance strength, mid-titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Concentra\u00e7\u00e3o-alvo equivalente cl\u00ednico (dose humana m\u00e1xima aprovada)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose arm, exploratory protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de v\u00e1rias semanas com um \u00fanico frasco, menor volume de reconstitui\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lower per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-month protocols, comparative dose-response studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose comparative arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, low per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudos multicohortes, protocolos de v\u00e1rios meses<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum Bulk packs vial, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All eleven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful for users minimising injection volume or running extended multi-month protocols from a single vial. Because reconstituted solution is stable for ~30 days, the optimal vial size for a given protocol depends on weekly dose \u00d7 weeks-per-vial trade-off. <\/p>\n<h2>Como Comparar \u2014 Tirzepatida vs Semaglutida vs Retatrutida<\/h2>\n<p>Tirzepatide sits at the centre of the modern incretin-agonist studies landscape, between the single-receptor <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> (somente GLP-1) e o triplo receptor <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (GLP-1 + GIP + glucagon). Each step up the receptor ladder produces a progressively larger body-weight effect in head-to-head studies but also broader systemic signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (\u00fanico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (duplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucagon (triplo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Coluna pept\u00eddica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP-like (39 aa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~120 horas (~5 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cadeia de \u00e1cido graxo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 di\u00e1cido + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c1cido C20 di\u00e1cido + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Refer\u00eancia de marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Investigacional (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132,4 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2,5\u201315 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal em ensaios<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22% (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Controle glic\u00eamico, cardiovascular<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Controle glic\u00eamico + peso corporal combinados, MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maior efeito sobre o peso corporal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The head-to-head SURPASS-2 trial (Frias et al., NEJM 2021) showed superior HbA1c and body-weight reduction with tirzepatide 15\u00a0mg vs semaglutide 1\u00a0mg over 40 weeks \u2014 one of the largest direct comparison datasets in incretin studies. For methodological detail on the dual- vs triple-agonist landscape, read <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida: agonista triplo vs duplo<\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide), magnitude of effect (greater with tirzepatide and retatrutide), and the strength of available trial data (extensive for semaglutide and tirzepatide, still maturing for retatrutide). <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220 \u00b0C. A tirzepatida liofilizada \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento-descongelamento no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco de pept\u00eddeo (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 10 mg, 2,0 mL de \u00e1gua bacteriost\u00e1tica produzem uma concentra\u00e7\u00e3o de trabalho de 5 mg\/mL \u2014 10 marcas em uma seringa de insulina U-100 equivalem a 500 mcg. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> sacuda \u2014 e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o reconstitu\u00edda corretamente deve estar l\u00edmpida e incolor. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because tirzepatide is dosed once weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20134 weeks of dosing depending on target dose; a 50\u00a0mg vial supports 10\u201320 weeks at clinical-equivalent doses. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Tirzepatide used for in studies?<\/h3>\n<p>Tirzepatide is used in studies investigating glycaemic control, insulin sensitivity, body weight and adiposity, MASLD\/MASH liver disease, cardiovascular endpoints, sleep apnoea, and diabetic nephropathy. It is the most extensively characterised dual GLP-1\/GIP agonist and is the standard comparator arm for newer multi-agonist peptide studies. The pharmaceutical-grade tirzepatide sold here is <strong>n\u00e3o<\/strong> FDA-approved for human therapeutic use and is supplied strictly for clinical studies. <\/p>\n<h3>Como a Tirzepatida difere da Semaglutida?<\/h3>\n<p>A diferen\u00e7a estrutural est\u00e1 no perfil de receptores e na cadeia pept\u00eddica. A tirzepatida \u00e9 constru\u00edda na cadeia de 39 amino\u00e1cidos do GIP e co-ativa tanto os receptores GIP quanto GLP-1. A semaglutida \u00e9 constru\u00edda na cadeia de 31 amino\u00e1cidos do GLP-1 e ativa apenas o receptor GLP-1. O componente GIP na tirzepatida adiciona lip\u00f3lise no tecido adiposo e aumentos modestos no gasto energ\u00e9tico que pept\u00eddeos exclusivos de GLP-1 n\u00e3o produzem. Em estudos comparativos (SURPASS-2), a tirzepatida 15 mg produziu redu\u00e7\u00e3o superior de HbA1c e peso corporal versus semaglutida 1 mg ao longo de 40 semanas. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre Tirzepatide e Retatrutide?<\/h3>\n<p>Ambos s\u00e3o baseados em GIP, mas o retatrutide adiciona atividade no receptor de glucagon al\u00e9m do GLP-1 e GIP \u2014 tornando-o um triplo agonista. O componente adicional de glucagon contribui ainda mais para o gasto energ\u00e9tico e a lip\u00f3lise dos adip\u00f3citos. Dados publicados da Fase 2 do retatrutide mostram uma redu\u00e7\u00e3o de ~24% no peso corporal com 12 mg semanais, superando modestamente os 22% do tirzepatide no estudo SURMOUNT-1. O tirzepatide possui um conjunto de dados de ensaios mais maduro; o retatrutide ainda est\u00e1 em desenvolvimento em est\u00e1gio avan\u00e7ado. <\/p>\n<h3>What is the typical Tirzepatide dose?<\/h3>\n<p>Protocolos publicados geralmente usam um esquema de titula\u00e7\u00e3o come\u00e7ando com 2,5 mg semanais e aumentando em 2,5 mg a cada 4 semanas at\u00e9 uma dose de manuten\u00e7\u00e3o de 5\u201315 mg semanais. Um frasco de 10 mg reconstitu\u00eddo com 2,0 mL de \u00e1gua bacteriost\u00e1tica rende 5 mg\/mL \u2014 10 marcas em uma seringa U-100 equivalem a 500 mcg. <\/p>\n<h3>O Tirzepatide \u00e9 aprovado pela FDA?<\/h3>\n<p>Pharmaceutical tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023), manufactured to GMP standards by Eli Lilly. <\/p>\n<h3>Como o Tirzepatide deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho em curto prazo, ou \u221220 \u00b0C para armazenamento em longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, usar dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento e descongelamento degradam o pept\u00eddeo. Proteja da luz direta em todos os momentos. <\/p>\n<h3>Como reconstituir o Tirzepatide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o liofilizado), agite suavemente e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 l\u00edmpida e incolor. Para um frasco de 10 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 5 mg\/mL. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries Tirzepatide in eleven lyophilized vial strengths: 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg, 80\u00a0mg, 100\u00a0mg, and 120\u00a0mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Qual \u00e9 a meia-vida do Tirzepatide?<\/h3>\n<p>O Tirzepatide tem uma meia-vida plasm\u00e1tica de aproximadamente 120 horas (~5 dias) ap\u00f3s administra\u00e7\u00e3o subcut\u00e2nea. A meia-vida \u00e9 alcan\u00e7ada pela liga\u00e7\u00e3o revers\u00edvel \u00e0 albumina s\u00e9rica circulante via o \u00e1cido di\u00e1cido graxo C20 na lisina 20, que protege o pept\u00eddeo da depura\u00e7\u00e3o renal. Combinado com a dupla substitui\u00e7\u00e3o de Aib (posi\u00e7\u00f5es 2 e 13) que bloqueia a clivagem pela DPP-4, isso confere ao Tirzepatide um regime de dosagem semanal compar\u00e1vel \u00e0 meia-vida de ~165 horas do semaglutida. <\/p>\n<h3>Por que o Tirzepatide produz mais perda de peso que o Semaglutida?<\/h3>\n<p>The most-cited mechanism is the GIP-receptor component. GIP-receptor activation contributes additional effects that GLP-1 alone doesn&#8217;t produce: enhanced adipocyte lipolysis under fasting conditions, modest increases in resting energy expenditure, and CNS effects in the dorsomedial hypothalamus distinct from arcuate-nucleus GLP-1 signalling. The combined dual signal produces an additive body-weight reduction beyond GLP-1 alone in head-to-head study models. <\/p>\n<h3>Does Tirzepatide cause side reported effects?<\/h3>\n<p>O achado mais consistente \u00e9 gastrointestinal \u2014 n\u00e1usea, supress\u00e3o transit\u00f3ria do apetite e esvaziamento g\u00e1strico retardado s\u00e3o dose-dependentes e tendem a atenuar ap\u00f3s 4\u20138 semanas de dosagem cont\u00ednua conforme a taquifilaxia do receptor se desenvolve. Achados menos comuns incluem efeitos na motilidade da ves\u00edcula biliar e (em modelos de roedores com sensibilidade de c\u00e9lulas C da tireoide) hiperplasia de c\u00e9lulas C \u2014 este \u00faltimo \u00e9 um sinal espec\u00edfico da esp\u00e9cie que n\u00e3o se traduziu em humanos em acompanhamento cl\u00ednico de longo prazo. <\/p>\n<h3>Can Tirzepatide and Semaglutide be compared in studies?<\/h3>\n<p>Sim \u2014 a compara\u00e7\u00e3o direta \u00e9 uma das quest\u00f5es mais ativamente estudadas na farmacologia dos incretinas. O ensaio cl\u00ednico SURPASS-2 comparou diretamente Tirzepatide 15 mg vs Semaglutida 1 mg em pacientes com diabetes tipo 2; evid\u00eancias pr\u00e9-cl\u00ednicas e crescentes do mundo real continuam a estender a compara\u00e7\u00e3o para peso corporal, MASH e desfechos cardiovasculares. O Semaglutida permanece como o comparador padr\u00e3o de GLP-1; o Tirzepatide \u00e9 o comparador padr\u00e3o de agonista duplo. <\/p>\n<h3>How long does Tirzepatide take to show effects in preclinical studies?<\/h3>\n<p>Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1\u20132 weeks of weekly dosing and continue to accrue through 8\u201316 weeks. Maximum effect on body composition is typically observed after 16\u201324 weeks of continuous dosing in study models, mirroring the human-trial trajectory. <\/p>\n<h3>Posso encomendar Tirzepatide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Tirzepatide para todo o mundo a partir de nossa rede dedicada de envio de pept\u00eddeos. Pedidos contendo apenas pept\u00eddeos qualificam-se para nosso servi\u00e7o de envio exclusivo para pept\u00eddeos. Todos os pedidos s\u00e3o enviados em embalagens com controle de temperatura com rastreamento completo e s\u00e3o cobertos pela nossa <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Reenvio Garantido<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Single GLP-1 agonist (Ozempic\/Wegovy\/Rybelsus active) \u2014 standard glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/pt-br\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 next-generation multi-axis metabolic support<\/li>\n<li><a href=\"\/pt-br\/tesamorelin\/\"><strong>Tesamorelina<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded exercise-mimetic peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/pt-br\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog for growth-axis studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Compare o cen\u00e1rio dos incret\u00ednicos de longa a\u00e7\u00e3o<\/strong><\/p>\n<p style=\"margin: 0;\">Leia nossos guias comparativos: <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\"><strong>Retatrutida vs Tirzepatida \u2014 agonista triplo vs dual<\/strong><\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. Abrange farmacologia de receptores, engenharia de sequ\u00eancia, meia-vida, resposta \u00e0 dose e os dados de ensaios comparativos que distinguem tirzepatida de semaglutida (SURPASS-2) e dos resultados de fase 2 da retatrutida como agonista triplo.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Coagonista dual dos receptores GLP-1 + GIP<br \/>\n\u2705 Maior efeito de perda de peso com um \u00fanico pept\u00eddeo<br \/>\n\u2705 Supports glycaemic control<br \/>\n\u2705 Lip\u00f3lise de adip\u00f3citos e gasto energ\u00e9tico<br \/>\n\u2705 Protocolos de dose semanal<\/p>\n<p><strong>Tirzepatide<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":["post-70674","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-tirzepatide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}